MARKET

COAG

COAG

HEMAB THERAPEUTICS HOLDINGS
NASDAQ
50.39
+3.08
+6.51%
Closed 19:34 07/27 EDT
OPEN
47.78
PREV CLOSE
47.31
HIGH
50.75
LOW
45.80
VOLUME
386.32K
TURNOVER
--
52 WEEK HIGH
52.15
52 WEEK LOW
23.00
MARKET CAP
2.35B
P/E (TTM)
-98.1496
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at COAG last week (0720-0724)?
Weekly Report · 1d ago
Biotech stocks lead healthcare's overbought list as earnings picks up
Seeking Alpha · 5d ago
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
NASDAQ · 07/21 07:41
Weekly Report: what happened at COAG last week (0713-0717)?
Weekly Report · 07/20 10:35
Hemab Presents Sutacimig Data; Wedbush Rates Outperform, $55 Target
NASDAQ · 07/15 11:08
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
Seeking Alpha · 07/15 07:52
Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating
TipRanks · 07/14 12:55
Hemab Therapeutics presents sutacimig data at ISTH Congress
TipRanks · 07/14 11:50
More
About COAG
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.

Webull offers Hemab Therapeutics Holdings, Inc. stock information, including NASDAQ: COAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COAG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COAG stock methods without spending real money on the virtual paper trading platform.